Harold Bernstein - 30 Jan 2025 Form 3 Insider Report for Maze Therapeutics, Inc. (MAZE)

Role
President, R&D & CMO
Signature
/s/ Courtney Phillips, as attorney-in-fact
Issuer symbol
MAZE
Transactions as of
30 Jan 2025
Transactions value $
$0
Form type
3
Filing time
30 Jan 2025, 16:22:45 UTC
Next filing
24 Sep 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding MAZE Stock Option (Right to Buy) 30 Jan 2025 Common Stock 387K $10.42 Direct F1
holding MAZE Stock Option (Right to Buy) 30 Jan 2025 Common Stock 25.9K $10.42 Direct F2
holding MAZE Stock Option (Right to Buy) 30 Jan 2025 Common Stock 142K $10.42 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
F2 The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on April 1, 2024, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
F3 The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on January 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.